Protein binding in plasma of valsartan, a new angiotensin II receptor antagonist

Journal of Clinical Pharmacology

Volumn 37, Issue 3, 1997, Pages 214-221

  Colussi, Danielle M ^a   Parisot, Carole ^a   Rossolino, Maria L ^a   Brunner, Linda A ^a   Lefèvre, Gilbert Y ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; DICLOFENAC; FUROSEMIDE; HUMAN SERUM ALBUMIN; HYDROCHLOROTHIAZIDE; IMMUNOGLOBULIN; OROSOMUCOID; PLASMA PROTEIN; VALSARTAN; WARFARIN;

ARTICLE; DRUG DISPOSITION; DRUG MECHANISM; DRUG PROTEIN BINDING; EQUILIBRIUM DIALYSIS; HUMAN; HYPERTENSION; MOUSE; NONHUMAN; RAT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

EID: 0030896929     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1002/j.1552-4604.1997.tb04783.x     Document Type: Article

References (13)

1. Criscione L, Bradley W, Bühlmayer P, Whitebread S, Glazer R, Lloyd P, et al: Valsartan: preclinical and clinical profile of an antihypertensive angiotensin-II antagonist. Cardiovasc Drug Rev 1995;13:230-250.
2. Buehlmayer P, Furet P, Criscione L, de Gasparo M, Whitebread S, Schmidlin T, et al: Valsartan, a potent, orally active angiotensin II antagonist developed from the structurally new amino acid series. Bioorganic Med Chem Lett 1994;4:29-34.
3. Flesch G, Müller P, Hell F, Degen P, Howald H, Dieterle W: Absolute oral bioavailability of valsartan in healthy volunteers. (abstract) Eur J Drug Metab Pharmacokinet 1996;163(suppl):34.
4. Müller P, Flesch G, de Gasparo M, Turri M, Preiswerk G, Howald H: Single- and multiple-dose phase I trials with the angiotensin II antagonist valsartan. J Hypertens 1993;11(suppl 5):S459-S460.
5. Waldmeier F, Flesch G, Müller P, Winkler T, Kriember HP, Bühlmayer P, de Gasparo M: The metabolism of valsartan in man. Xenobiotica, in press.
6. Corea L, Cardoni O, Fogari R, Innocenti P, Porcellati C, Provvidenza M, et al: Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: a comparative study of the efficacy and safety against amlodipine. Clin Pharmacol Ther 1996;60:341-346.
7. Brunner L, Powell M, Degen P, Flesch G: A semi-automated analytical method for the determination of potential antihypertensive agents, CGP 48933 and CGP 48369, in human plasma using high-performance liquid chromatography. Lab Rob Automation 1994;6:171-179.
8. Riess W, Stierlin H, Faigle JW, Geiger UP, Gérardin, Scmid K, et al: Kinetic und Biotransformation von Diclofenac in Tier und Mensch. Therapiewoche 1976;26:18.
9. Prandota J, Pruitt A: Furosemide binding to human albumin and plasma of nephrotic children. Clin Pharmacol Ther 1975; 17:159-166.
10. O'Byrne S, Barry M, Collins W, O'Connor P, Cullen M, Feely J: Plasma protein binding of lidocaine and warfarin in insulin-dependent and non-insulin-dependent diabetes mellitus. Clin Pharmacokinet 1993;24:183-186.
11. Vozeh S, Taeschner W, Wenk M: Pharmacokinetic drug data. In, Mammen GJ (ed.): Clinical Pharmacokinetics, Drug Data Handbook. Langhorne, PA: Ads Press. 1990;24.
12. Beermann B, Groschinsky-Grind M, Rosen A: Absorption and excretion of hydrochlorothiazide. Clin Pharmacol Ther 1976; 19:531-537.
13. Christ D: Human plasma protein binding of the angiotensin II receptor antagonist losartan potassium (DuP 753/MK 954) and its pharmacologically active metabolite EXP3174. J Clin Pharmacol 1995;35:515-520.